FDA leadership began another round of upheaval after commissioner Marty Makary resigned, according to multiple reports. The shakeup is already rippling through the agency’s drug review leadership and internal decision-making. Reuters reported that Tracy Beth Høeg, M.D., Ph.D.—acting director of the Center for Drug Evaluation and Research (CDER) after Richard Pazdur’s departure—was expected to leave the agency as well, citing sources familiar with internal plans. A separate report framed the likely broader churn across U.S. health agencies. The personnel moves increase near-term regulatory uncertainty for biopharma companies managing clinical timelines, submissions, and interactions with FDA offices amid shifting leadership bandwidth.